Search Results for "Lung"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for Lung. Results 201 to 210 of 220 total matches.
Budesonide/Formoterol (Symbicort) for Asthma
The Medical Letter on Drugs and Therapeutics • Feb 11, 2008 (Issue 1279)
inhalation twice daily
were similarly effective in improving lung function,
asthma symptoms ...
A combination of the corticosteroid budesonide and the long-acting beta2-agonist formoterol (Symbicort - AstraZeneca) has become available in a metered dose inhaler for long-term maintenance treatment of asthma in patients ≥ 12 years old. A combination product that contains fluticasone propionate and salmeterol (Advair) is already available for this indication in the US. Neither one of these combinations is approved for acute treatment of asthma symptoms. A dry powder inhaler formulation of Symbicort has been available in Europe and Canada for several years.
Expanded Table: Some Available Insulins for Type 2 Diabetes (online only)
The Medical Letter on Drugs and Therapeutics • May 06, 2019 (Issue 1571)
for use in patients with
chronic lung disease such as asthma or
COPD; acute bronchospasm has occurred ...
View the Expanded Table: Some Available Insulins
Two New Pneumococcal Vaccines - Prevnar 20 and Vaxneuvance
The Medical Letter on Drugs and Therapeutics • Nov 29, 2021 (Issue 1638)
conditions include alcohol use disorder, chronic heart, liver, or lung disease, and diabetes mellitus.
190 ...
The FDA has licensed two new pneumococcal
conjugate vaccines (PCVs) for prevention of invasive
pneumococcal disease in adults: Prevnar 20 (PCV20;
Pfizer), which contains antigens from 20 serotypes of
pneumococcus, and Vaxneuvance (PCV15; Merck),
which contains antigens from 15 serotypes. Two
other pneumococcal vaccines are available in the
US: Prevnar 13 (PCV13; Pfizer), a 13-valent conjugate
vaccine licensed for use in persons ≥6 weeks old,
and Pneumovax 23 (PPSV23; Merck), a 23-valent
pneumococcal polysaccharide vaccine licensed for
use in persons ≥2 years...
Vanzacaftor, Tezacaftor, and Deutivacaftor (Alyftrek) for Cystic Fibrosis
The Medical Letter on Drugs and Therapeutics • Mar 17, 2025 (Issue 1724)
advantage over Trikafta in preserving
lung function or preventing pulmonary exacerbations
remains ...
The FDA has approved Alyftrek (Vertex), an oral
fixed-dose combination of the cystic fibrosis
transmembrane conductance regulator (CFTR)
modulators vanzacaftor, tezacaftor, and deutivacaftor,
for once-daily treatment of cystic fibrosis (CF) in
patients ≥6 years old who have at least one F508del
mutation or another responsive mutation in the
CFTR gene. This is the first approval for vanzacaftor
and for deutivacaftor, a deuterated form of ivacaftor.
Trikafta, a twice-daily oral fixed-dose combination of
elexacaftor, tezacaftor, and ivacaftor, is FDA-approved
for the same indication...
Med Lett Drugs Ther. 2025 Mar 17;67(1724):41-3 doi:10.58347/tml.2025.1724a | Show Introduction Hide Introduction
Fluticasone Furoate (Veramyst) for Allergic Rhinitis
The Medical Letter on Drugs and Therapeutics • Nov 05, 2007 (Issue 1273)
fluticasone furoate in vitro and in an in
vivo model of respiratory inflammatory disease. Am J Physiol
Lung ...
Fluticasone furoate nasal spray (Veramyst - GSK) is now available for once-daily treatment of seasonal and perennial allergic rhinitis in adults and children ≥2 years old. It is similar to fluticasone propionate nasal spray (Flonase, and others), which is now available generically.
Drugs for Tuberculosis
Treatment Guidelines from The Medical Letter • Apr 01, 2012 (Issue 116)
corticosteroid drugs and
in those with kidney, heart or lung transplants.46 QT
interval prolongation can occur ...
Tuberculosis (TB) is still a common cause of death
worldwide, and the prevalence of drug-resistant TB
poses challenges to its treatment and control.
Guidelines with detailed management recommendations
are available from the American Thoracic
Society, Centers for Disease Control and Prevention
(CDC) and Infectious Diseases Society of America
(IDSA).
Drugs for Psoriatic Arthritis
The Medical Letter on Drugs and Therapeutics • Dec 30, 2019 (Issue 1588)
-Johnson syndrome, weight
loss, interstitial lung disease, peripheral neuropathy,
and leukocytoclastic ...
Psoriatic arthritis is a chronic inflammatory
arthropathy associated with psoriasis. A recent review
found that about 20% of patients with psoriasis have
psoriatic arthritis. Updated guidelines for treatment
of psoriatic arthritis have recently been published.
Intravenous Immunoglobulin (IVIG)
The Medical Letter on Drugs and Therapeutics • Dec 04, 2006 (Issue 1249)
, vomiting and hypotension. Hemolysis and acute lung injury
can occur. One retrospective review found ...
Intravenous immunoglobulin (IVIG) has 6 FDA approved indications and is prescribed off-label for many others. How many of these uses are justified is controversial.
Drugs of Choice for Cancer
Treatment Guidelines from The Medical Letter • Mar 01, 2003 (Issue 7)
or cisplatin Doxorubicin; fluorouracil; mitomycin
Lung
Non-small cell Paclitaxel + either carboplatin ...
The tables in this article list drugs used for treatment of cancer in the USA and Canada and their major adverse effects. The choice of drugs in Table I is based on the opinions of Medical Letter consultants. Some drugs are listed for indications for which they have not been approved by the US Food and Drug Administration. In some cases, such as elderly patients or those with many co-morbid illnesses, the regimen of choice might not be suitable. For many of the cancers listed, surgery and/or radiation therapy may be the treatment of choice or may also be part of the management. Anticancer...
Drugs for Alcohol Use Disorder
The Medical Letter on Drugs and Therapeutics • Dec 13, 2021 (Issue 1639)
is excreted unchanged in
feces, as metabolites in urine, and as carbon disulfide
by the lungs.
Clinical ...
Consumption of alcohol has increased during the
COVID-19 pandemic. The Diagnostic and Statistical
Manual for Mental Disorders, 5th edition (DSM-5) defines
alcohol use disorder (AUD; previously called alcohol
dependence) as meeting ≥2 of the 11 criteria listed in
Table 1 in the past year. The lifetime prevalence of AUD
in the US population has been estimated to be about
30%. Despite this high prevalence and the associated
morbidity, mortality, and costs, only 3 drugs are FDA-approved
for treatment of the disorder.